Methods and systems for pharmacogenomic treatment of cardiovascular conditions
Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rostafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an indentified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.
1. A method comprising:
administering Rostafuroxin once a day in an amount of 0.005 mg to 5.0 mg/day to treat or prevent a cardiovascular condition in an individual genotyped as having at least one genotype selected from the group consisting of genotype TT for rs2345088, genotype C/T for rs16877182, genotype AA for rs16893522, genotype AA for rs2461911, genotype TT for rs5013093, and genotype TT for rs12513375.
2. The method of claim 1 , wherein the individual has been further genotyped for at least one polymorphism selected from the group consisting of rs4961, rs4984, rs3731566, rs914247, rs1045642, rs242093, rs1996396, rs10503806, rs13251780, rs17430706, rs10102024, rs526302, rs544104, rs3102087, rs5183, rs3772627, rs2276736, rs2131127, rs3741559, rs2217342, rs10927888, rs6604909, rs945403, rs7117314, rs10790212, rs11216598, rs910682, rs13218316, rs4309483, rs13280307, rs4739037, rs17596774, rs2728108, rs17786456, rs7696304, rs2725222, rs17199565, rs2758152, rs1057293, rs16960712, rs759359, rs404214, rs1005213, rs17025453, rs2110923, rs1428571, rs435404, rs12908787, rs11647727, rs880054, rs11064584, rs12996186, rs9893372, rs7216331, rs7521668, rs188334, rs4998662, rs16893522, rs6457110, rs3893464, rs2517718, rs1362126, rs5013093, rs2345088, rs6718282, rs721207, rs2555500, rs2461911, rs8179654, rs1901139, rs2427832, rs9361863, rs1998394, ga001619, rs2275531, rs748140, rs4710592, rs2743951, rs10159569, rs3087816, rs10493940, rs16877182, rs2326912, rs1110446, rs12513375, and rs17414954.
3. The method of claim 1 , wherein the individual has been further genotyped for at least one single nucleotide polymorphisms selected from the group consisting of rs4961, rs4984, rs3731566, rs914247, and rs1045642.
4. The method of claim 1 , wherein the individual has been further genotyped for of at least one genotype selected from the group consisting of GT for rs4961, CT for rs4984, AG for rs3731566, GA for rs914247, and TC for rs1045642.
5. The method of claim 1 , wherein the individual has been genotyped for a genotype AA for rs914247.
6. The method of claim 1 , wherein the individual has been further genotyped for at least one single nucleotide polymorphism selected from the group consisting of rs242093, rs1996396, rs10503806, rs13251780, rs17430706, rs10102024, rs526302, rs544104, rs3102087, rs5183, rs3772627, rs2276736, rs2131127, rs3741559, rs2217342, rs10927888, rs6604909, rs945403, rs7117314, rs10790212, rs11216598, rs910682, rs13218316, rs4309483, rs13280307, rs4739037, rs17596774, rs2728108, rs17786456, rs7696304, rs2725222, rs17199565, rs2758152, rs1057293, rs16960712, rs759359, rs404214, rs1005213, rs17025453, rs2110923, rs1428571, rs435404, rs12908787, rs11647727, rs880054, and rs11064584.
7. The method of claim 1 , wherein the individual has been further genotyped for at least one additional single nucleotide polymorphism selected from the group consisting of rs12996186, rs9893372, rs7216331, rs7521668, rs188334, rs4998662, rs16893522, rs6457110, rs3893464, rs2517718, rs1362126, rs5013093, rs2345088, rs6718282, rs721207, rs2555500, rs2461911, rs8179654, rs1901139, rs2427832, rs9361863, rs1998394, ga001619, rs2275531, rs748140, rs4710592, rs2743951, rs10159569, rs3087816, rs10493940, rs16877182, rs2326912, rs1110446, rs12513375, and rs17414954.
8. The method of claim 1 , wherein the individual has been genotyped for at least one single nucleotide polymorphism selected from the group consisting of rs4961, rs4984, rs10923835, rs947130, rs914247, rs1045642, rs880054, rs10502933, rs2131127, rs4309483, and rs4739037.
9. The method of claim 1 , wherein the individual has been further genotyped for at least one single nucleotide polymorphism selected from the group consisting of rs1045642, rs10923835, rs914247, rs4961, rs947130, rs4309483, rs2131127, rs10502933, and rs880054.
10. The method of claim 1 , wherein the individual has been further genotyped for at least one single nucleotide polymorphism elected from the group consisting of rs1045642, rs10923835, rs914247, rs947130, rs4739037, rs43909483, rs4984, rs10502933 and rs880054.
11. The method of claim 1 , where the cardiovascular condition is hypertension and/or a condition associated thereto.
12. The method of claim 11 , wherein the cardiovascular condition associated thereto is at least one of cardiac hypertrophy, cardiac insufficiency, cardiac failure, cardiac ischemia, increased vascular resistances, increased vascular reactivity, vascular stiffness, increased vascular thickness, renal hypertrophy, renal failure, glomerulosclerosis, proteinuria, polycistic renal disease, retinal damage, cerebrovascular disorders, cerebrovascular damage, stroke, Meniere syndrome, cognitive disorders, and bipolar disorders.
13. The method according to claim 1 , wherein the administering is performed by administering 0.05 mg to 0.15 mg/day of Rostafuroxin.
14. The method according to claim 1 , wherein the administering is performed by administering 0.01 mg to 1.5 mg/day of Rostafuroxin.
15. The method according to claim 1 , wherein the administering is performed by administering 0.05 mg to 0.5 mg/day of Rostafuroxin.
16. A method comprising:
administering Rostafuroxin in a dosage of from 0.005 mg/day to 5 mg/day, to an individual genotyped as having a genotype comprising at least one of genotype TT for rs2345088, genotype C/T for rs16877182, genotype AA for rs16893522, genotype AA for rs2461911, genotype TT for rs5013093, and genotype TT for rs12513375.
17. The method of claim 16 , wherein treatment with Rostafuroxin is directed to at least one biological activity selected from the group consisting of elective inhibition of the ouabain hypertensive effect, normalization of alterations in the Na—K pump and Src caused by ouabain, normalization in forms of hypertension sustained by the concomitant increase of endogenous ouabain levels and alterations in the Na—K pump and Src.
18. The method of claim 16 , wherein treatment with Rostafuroxin is directed to elicit at least one biological activity selected from the group consisting of selective antagonism of the hypertensive effect associated to the genetic variations of genes coding for adducin or other enzymes involved in synthesis and transport of endogenous ouabain, normalization of alterations in the Na—K pump and Src caused by adducin genetic variations, and normalization in forms of hypertension sustained by the concomitant effects of adducin genetic variations and alterations in the Na—K pump and Src.
19. The method of claim 16 , wherein the dosage is from 0.05 mg/day to 0.15 mg/day.
20. The method of claim 16 , wherein the dosage is from 1.5 mg/day to 5.0 mg/day.
21. The method of claim 16 , wherein the dosage is from 0.05 mg/day to 1.5 mg/day.
22. The method of claim 16 , wherein the individual has been further genotyped for at least one polymorphism selected from the group consisting of rs4961, rs4984, rs3731566, rs914247, rs1045642, rs242093, rs1996396, rs10503806, rs13251780, rs17430706, rs10102024, rs526302, rs544104, rs3102087, rs5183, rs3772627, rs2276736, rs2131127, rs3741559, rs2217342, rs10927888, rs6604909, rs945403, rs7117314, rs10790212, rs11216598, rs910682, rs13218316, rs4309483, rs13280307, rs4739037, rs17596774, rs2728108, rs17786456, rs7696304, rs2725222, rs17199565, rs2758152, rs1057293, rs16960712, rs759359, rs404214, rs1005213, rs17025453, rs2110923, rs1428571, rs435404, rs12908787, rs11647727, rs880054, rs11064584, rs12996186, rs9893372, rs7216331, rs7521668, rs188334, rs4998662, rs16893522, rs6457110, rs3893464, rs2517718, rs1362126, rs5013093, rs2345088, rs6718282, rs721207, rs2555500, rs2461911, rs8179654, rs1901139, rs2427832, rs9361863, rs1998394, ga001619, rs2275531, rs748140, rs4710592, rs2743951, rs10159569, rs3087816, rs10493940, rs16877182, rs2326912, rs1110446, rs12513375, and rs17414954.
23. The method of claim 22 , wherein the administering is performed through an administration route selected from the group consisting of oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, rectal means or locally on the diseased tissue after surgical operation.
24. A method comprising:
assaying an individual using nucleic acid probes for at least one genotype selected from the group consisting of genotype TT for rs2345088, genotype C/T for rs16877182, genotype AA for rs16893522, genotype AA for rs2461911, genotype TT for rs5013093, and genotype TT for rs12513375;
detecting the presence of said at least one genotype; and
administering Rostafuroxin to the individual to treat or prevent a cardiovascular condition.
25. A method comprising:
assaying an individual using nucleic acid probes for at least one genotype selected from the group consisting of genotype TT for rs2345088, genotype C/T for rs16877182, genotype AA for rs16893522, genotype AA for rs2461911, genotype TT for rs5013093, and genotype TT for rs12513375;
detecting the presence of said at least one genotype; and
administering Rostafuroxin once a day in an amount of 0.005 mg to 5.0 mg/day to the individual to treat or prevent the cardiovascular condition.